logo-loader
viewScancell Holdings PLC

Scancell Holdings CEO discusses new research programme into coronavirus vaccine

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway speaks to Proactive London's Andrew Scott after revealing it's begun a research programme to develop a vaccine for the coronavirus.

The project, to be led by the company’s chief scientific officer Lindy Durrant, will aim to use the company’s clinical expertise in cancer to produce a cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against coronavirus.

Quick facts: Scancell Holdings PLC

Price: 5.35 GBX

LSE:SCLP
Market: LSE
Market Cap: £24.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 on back foot over fears it could take years to find...

Headlines from the Proactive UK newsroom. The FTSE 100 is on the back foot on fears it might take years to find an effective vaccine or treatment against coronavirus. The blue-chip index dropped 70 points to 5,755. Overnight, US firm Gilead Sciences terminated a highly anticipated Chinese...

on 24/4/20

2 min read